BVF Inc. IL lessened its holdings in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX – Free Report) by 9.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 508,031 shares of the company’s stock after selling 50,000 shares during the quarter. Abivax comprises approximately 2.3% of BVF Inc. IL’s holdings, making the stock its 14th largest position. BVF Inc. IL owned approximately 0.64% of Abivax worth $68,511,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of ABVX. Bank of America Corp DE raised its stake in shares of Abivax by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after buying an additional 1,990 shares in the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of Abivax by 34.3% in the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after buying an additional 2,595 shares in the last quarter. Millennium Management LLC raised its stake in shares of Abivax by 6.0% in the 1st quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock worth $6,171,000 after buying an additional 56,235 shares in the last quarter. Woodline Partners LP raised its stake in shares of Abivax by 319.5% in the 1st quarter. Woodline Partners LP now owns 201,924 shares of the company’s stock worth $1,262,000 after buying an additional 153,788 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Abivax in the 2nd quarter worth $139,000. Institutional investors own 47.91% of the company’s stock.
Abivax Stock Up 2.7%
Shares of Abivax stock opened at $100.15 on Thursday. The stock’s fifty day moving average is $114.81 and its 200-day moving average is $118.49. The firm has a market capitalization of $7.99 billion, a PE ratio of -19.22 and a beta of 0.69. Abivax SA Sponsored ADR has a 12-month low of $5.69 and a 12-month high of $148.83.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on ABVX. Jefferies Financial Group downgraded Abivax from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $160.00 to $90.00 in a research note on Tuesday, June 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research note on Monday, April 20th. BTIG Research reissued a “buy” rating and issued a $150.00 price objective on shares of Abivax in a research note on Tuesday. Truist Financial dropped their price objective on Abivax from $140.00 to $135.00 and set a “buy” rating on the stock in a research note on Tuesday, June 2nd. Finally, Oddo Bhf reissued an “outperform” rating on shares of Abivax in a research note on Thursday, April 9th. Twelve research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $130.08.
View Our Latest Report on ABVX
Abivax Company Profile
Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.
Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.
Featured Articles
- Five stocks we like better than Abivax
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
